Media

News

Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.

February 21, 2019

Bayer’s darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival by 22 months, with a favourable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer

Darolutamide significantly improved median metastasis-free survival (MFS) by 22 months (40.4 months with darolutamide plus androgen deprivation therapy (ADT) versus 18.4 months for placebo plus ADT / Positive trend in overall survival with a 29% reduction in risk of death at interim analysis (P=0.045) / Incidence of treatment-emergent adverse events was similar between darolutamide plus ADT and placebo plus ADT/ Health-related quality of life was maintained/ First results from the Phase III ARAMIS trial with the androgen receptor antagonist darolutamide were presented in an oral presentation at American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019 and simultaneously published in The New England Journal of Medicine Read more
January 16, 2019

Does your community charity need some TLC?

$165,000 in community grants available to charities & not-for-profits across Canada through the 2019 Canada’s Farmers Grow Communities Program Read more
January 08, 2019

China grants regulatory approval of TruFlex™ canola with Roundup Ready® Technology

Farmers will have access to new varieties in time for 2019 spring planting Read more
November 29, 2018

Bayer to strengthen core life science businesses while significantly enhancing productivity and profitability

Group to take comprehensive range of portfolio, efficiency and structural measures Read more
November 28, 2018

Bayer and 4-H Canada Renew National Partnership with a Focus on Engaging Youth in STEM

Read more
November 07, 2018

Phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer meets primary endpoint

The safety and tolerability observed in the trial were consistent with previously published data on darolutamide Read more
November 01, 2018

From farmer to community hero

$165,000 shared with 66 rural charities & not-for-profits across Canada through the Canada’s Farmers Grow Communities Program Read more
October 24, 2018

Bayer Inc. receives approval for hemophilia A treatment Jivi®

Read more
October 02, 2018

Opportunity Scholarships awarded to students pursuing education in agriculture and food-related fields

Monsanto Fund, a philanthropic arm of Bayer, shares over $100,000 with deserving students from rural and urban locations across Canada Read more
September 25, 2018

Next generation of agricultural talent invited to ‘plant their path’ at the 2019 Youth Ag Summit in Brazil

Read more